Premium
Involvement of FGF‐2 in the action of Emdogain ® on normal human osteoblastic activity
Author(s) -
Mizutani S,
Tsuboi T,
Tazoe M,
Koshihara Y,
Goto S,
Togari A
Publication year - 2003
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1034/j.1601-0825.2003.02876.x
Subject(s) - fibroblast growth factor , cell growth , fibroblast , alkaline phosphatase , chemistry , osteoblast , cell , matrix metalloproteinase , endocrinology , medicine , microbiology and biotechnology , biology , enzyme , biochemistry , in vitro , receptor
Objective: The present study was designed to evaluate the pharmacological characteristics of Emdogain (EMD) on cell growth and cell activity in human osteoblasts. Methods: Cell proliferation as well as several gene and protein expressions were examined using reverse transcription‐polymerase chain reaction (RT‐PCR) and enzyme‐linked immunosorbent assay (ELISA) procedures in human osteoblastic cells (SaM‐1) treated with EMD (30 μ g ml −1 ). Results: Treatment of osteoblasts with EMD significantly stimulated cell proliferation and fibroblast growth factor (FGF)‐2 expression but decreased alkaline phosphatase expression. In addition, increases in cyclooxygenase (COX)‐2 expression and decreases in matrix metalloproteinases (MMP)‐1 expression were observed in osteoblasts treated with EMD. The effects of EMD on FGF‐2 and MMP‐1 expressions were not observed in osteoblasts treated with NS‐398, an inhibitor of COX‐2. The decrease in MMP‐1 mRNA by EMD was prevented by treatment with antisense oligodeoxynucleotide (AS‐ODN) for FGF‐2. Conclusion: Emdogain showing both stimulation of cell proliferation and inhibition of cell differentiation has been shown to increase FGF‐2 expression in the mediation of prostaglandin E 2 and to decrease MMP‐1 mRNA expression through the activation of FGF‐2. FGF‐2 may underlie in the action of EMD on osteoblasts during periodontal regeneration.